Smith & Nephew Beheer

Beheer criteriumcontroles 3/4

De CEO Smith & Nephew is Deepak Nath, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.66M, bestaande uit 32.5% salaris en 67.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.018% van de aandelen van het bedrijf, ter waarde € 1.92M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 2.8 jaar.

Belangrijke informatie

Deepak Nath

Algemeen directeur

US$4.7m

Totale compensatie

Percentage CEO-salaris	32.5%
Dienstverband CEO	2.6yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	2.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Deepak Nath's beloning veranderd ten opzichte van Smith & Nephew's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 29 2024	n/a	n/a	US$305m
Mar 29 2024	n/a	n/a	US$284m
Dec 31 2023	US$5m	US$2m	US$263m
Sep 30 2023	n/a	n/a	US$241m
Jul 01 2023	n/a	n/a	US$218m
Apr 01 2023	n/a	n/a	US$221m
Dec 31 2022	US$6m	US$1m	US$223m

Compensatie versus markt: De totale vergoeding ($USD 4.66M ) Deepak } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.86M ).

Compensatie versus inkomsten: De vergoeding van Deepak is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Deepak Nath (52 yo)

2.6yrs

Tenure

US$4,658,252

Compensatie

Dr. Deepak S. Nath, Ph D., serves as Director at Smith & Nephew plc since April 1, 2022. He served as Head of Diagnostics at Siemens Healthineers AG since 2021 until 2022 and served as its President of Lab...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Deepak Nath	CEO & Director	2.6yrs	US$4.66m	0.018% € 1.9m
John Rogers	CFO & Executive Director	less than a year	geen gegevens	geen gegevens
Paul Connolly	President of Global Operations	3.1yrs	geen gegevens	0.0019% € 194.8k
Andrew Swift	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Helen Barraclough	Group General Counsel & Company Secretary	2.8yrs	geen gegevens	0.0040% € 416.7k
Alison Parkes	Chief Compliance Officer & Compliance APAC	2.8yrs	geen gegevens	0.00025% € 26.0k
Joe Metzger	Senior Vice President of Marketing Services & Communications	13.8yrs	geen gegevens	geen gegevens
Philip Cowdy	Chief Corporate Development & Corporate Affairs Officer	no data	geen gegevens	0.0066% € 691.8k
Elga Lohler	Chief Human Resources Officer	8.9yrs	geen gegevens	0.019% € 1.9m
Vasant Padmanabhan	President of Research & Development and Ear	8.3yrs	geen gegevens	0.014% € 1.5m
Steve Kane	Head of Human Resources for the US	no data	geen gegevens	geen gegevens
Ian Melling	Senior Vice President of Group Finance	no data	geen gegevens	geen gegevens

3.0yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NPW1 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Deepak Nath	CEO & Director	2.6yrs	US$4.66m	0.018% € 1.9m
John Rogers	CFO & Executive Director	less than a year	geen gegevens	geen gegevens
Marc Owen	Independent Director	7.1yrs	US$206.78k	0.0020% € 206.3k
Simon Lowth	Independent Non-Executive Director	less than a year	geen gegevens	0.000030% € 3.1k
Rupert Soames	Independent Non-Executive Chairman	1.6yrs	US$180.82k	0.0023% € 236.5k
Angela Risley	Senior Independent Director	7.2yrs	US$118.56k	0.00069% € 71.9k
Changzheng Ma	Independent Non-Executive Director	3.8yrs	US$171.78k	0.00024% € 25.0k
Jeremy Maiden	Independent Non-Executive Director	1.2yrs	US$26.24k	0.00015% € 15.6k
Katarzyna Mazur-Hofsaess	Independent Non-Executive Director	4yrs	US$93.06k	0.00021% € 21.9k
Joanna Hallas	Independent Non-Executive Director	2.8yrs	US$93.06k	0.00065% € 67.7k
Robert White	Independent Non-Executive Director	4.5yrs	US$164.78k	0.00093% € 96.9k

2.8yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NPW1 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.8 jaar), wat duidt op een nieuw bestuur.

Smith & Nephew Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Recent updates

Smith & Nephew plc Provides Earnings Guidance for the Full Year 2024 and for 2025

Investor sentiment deteriorates as stock falls 17%

Smith & Nephew plc to Report Fiscal Year 2024 Results on Feb 25, 2025

Smith+Nephew Announces LEGION Hinged Knee System Now Available in the United States with Proprietary OXINIUM (Oxidized Zirconium)

Smith+Nephew Announces Board and Committee Changes

Upcoming dividend of US$0.14 per share

First half dividend of US$0.14 announced

First half 2024 earnings released: EPS: US$0.24 (vs US$0.20 in 1H 2023)

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

New minor risk - Earnings quality

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Final dividend of US$0.23 announced

Smith & Nephew plc Provides Earnings Guidance for 2024

Full year 2023 earnings released: EPS: US$0.30 (vs US$0.26 in FY 2022)

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Upcoming dividend of US$0.14 per share at 3.1% yield

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc Increases Revenue Guidance for 2023

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Now 21% undervalued

Insider recently bought €132k worth of stock

Upcoming dividend of US$0.23 per share at 2.6% yield

Chief Human Resources Officer recently sold €125k worth of stock

Full year 2022 earnings released: EPS: US$0.26 (vs US$0.60 in FY 2021)

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

High number of new directors

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Upcoming dividend of US$0.14 per share

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Chairman recently bought €70k worth of stock

First half 2022 earnings released

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Announces Executive Changes

Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation

High number of new directors

Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors

Upcoming dividend of US$0.23 per share

Independent Non-Executive Director recently bought €71k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Smith & Nephew plc, Annual General Meeting, Apr 13, 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION

Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems